Intest Res.  2019 Jan;17(1):45-53. 10.5217/ir.2018.00113.

Improving the quality of care for inflammatory bowel disease

Affiliations
  • 1Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. bdye@amc.seoul.kr
  • 2Translational Gastroenterology Unit, Oxford University Hospitals, Oxford, UK.

Abstract

Great strides have been achieved in the development of quality-of-care measures and standards for inflammatory bowel disease (IBD) over the last decade. The central structural component of care in IBD revolves around the multidisciplinary team, which should be equipped with the necessary resources to operate and implement decisions. Process measures have been defined by interest groups and can be adapted into process tools for the delivery of care for various patient subgroups and clinical scenarios. The emerging treat-to-target approach to IBD management may be used to achieve optimal long-term and holistic patient-centred outcomes, such as survival, control of inflammation and disease progression, symptomatic remission, quality of life and complications. Other important quality-of-care outcome measures for IBD include disutility of care, healthcare utilization and other patient-reported outcomes such as nutritional status and impact of fistulae. The current challenge for healthcare providers and health systems is the integration of quality-of-care structures and processes into clinical practice, and the consistent delivery of updated evidence-based quality IBD care to various patient populations by individual health care providers. Finally, the awareness and appreciation for quality of care in IBD is increasing in Asia, and Asian healthcare institutions should be encouraged to take the lead in improving the quality of care in IBD.

Keyword

Inflammatory bowel disease; Quality of care; Health system; Treat to target

MeSH Terms

Asia
Asian Continental Ancestry Group
Delivery of Health Care
Disease Progression
Fistula
Health Personnel
Humans
Inflammation
Inflammatory Bowel Diseases*
Nutritional Status
Outcome Assessment (Health Care)
Process Assessment (Health Care)
Public Opinion
Quality of Life

Figure

  • Fig. 1. The Donabedian framework for evaluating quality of healthcare.


Cited by  3 articles

Classification According to Subjectivity of Inflammatory Bowel Disease Patients Using Q Methodology
Jun Lee
Korean J Gastroenterol. 2021;78(1):1-2.    doi: 10.4166/kjg.2021.103.

염증성 장질환 환자의 치료에 대한 주관적인 필요와 생각: Q 방법론 적용
Yong Eun Park, Jin Lee, Jongha Park, Joon Hyuk Choi, Nae Yun Heo, Seung Ha Park, Yoon Kyoung Lee, Tae Oh Kim
Korean J Gastroenterol. 2021;78(1):37-47.    doi: 10.4166/kjg.2021.053.

Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen
Intest Res. 2020;18(1):18-33.    doi: 10.5217/ir.2019.09155.


Reference

1. Berry SK, Siegel CA, Melmed GY. Quality improvement initiatives in inflammatory bowel disease. Curr Gastroenterol Rep. 2017; 19:41.
Article
2. Harbord M, Eliakim R, Bettenworth D, et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis. 2017; 11:769–784.
Article
3. Donabedian A. The quality of care. How can it be assessed? JAMA. 1988; 260:1743–1748.
Article
4. Kim AH, Roberts C, Feagan BG, et al. Developing a standard set of patient-centred outcomes for inflammatory bowel disease-an international, cross-disciplinary consensus. J Crohns Colitis. 2018; 12:408–418.
Article
5. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington DC: National Academies Press (US);2001.
6. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013; 19:662–668.
7. Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005; 100:1357–1361.
Article
8. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010; 31:693–707.
Article
9. Porter ME. What is value in health care? N Engl J Med. 2010; 363:2477–2481.
Article
10. Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence. 2017; 11:947–958.
Article
11. Veilleux S, Noiseux I, Lachapelle N, et al. Patients’ perception of their involvement in shared treatment decision making: key factors in the treatment of inflammatory bowel disease. Patient Educ Couns. 2018; 101:331–339.
Article
12. Kelso M, Feagins LA. Can smartphones help deliver smarter care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2018; 24:1453–1459.
Article
13. Porter ME, Lee TH. From volume to value in health care: the work begins. JAMA. 2016; 316:1047–1048.
14. Hibi T, Panaccione R, Katafuchi M, et al. The 5C concept and 5S principles in inflammatory bowel disease management. J Crohns Colitis. 2017; 11:1302–1308.
Article
15. Morar P, Read J, Arora S, et al. Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study. Frontline Gastroenterol. 2015; 6:290–297.
Article
16. Lee CK, Melmed GY. Multidisciplinary team-based approaches to IBD management: how might “One-Stop Shopping” work for complex IBD care? Am J Gastroenterol. 2017; 112:825–827.
Article
17. Calvet X, Panés J, Alfaro N, et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis. 2014; 8:240–251.
Article
18. Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014; 46:1017–1020.
Article
19. Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015; 13:193–207.
Article
20. Tkacz J, Brady BL, Meyer R, Lofland JH, Ruetsch C, Coelho-Prabhu N. An assessment of the AGA and CCFA quality indicators in a sample of patients diagnosed with inflammatory bowel disease. J Manag Care Spec Pharm. 2015; 21:1064–1076.
Article
21. Song HK, Lee KM, Jung SA, et al. Quality of care in inflammatory bowel disease in Asia: the results of a multinational webbased survey in the 2nd Asian Organization of Crohn’s and Colitis (AOCC) meeting in Seoul. Intest Res. 2016; 14:240–247.
Article
22. Bryant RV, Costello SP, Schoeman S, et al. Limited uptake of ulcerative colitis “treat-to-target” recommendations in realworld practice. J Gastroenterol Hepatol. 2018; 33:599–607.
Article
23. Nakase H, Keum B, Ye BD, Park SJ, Koo HS, Eun CS. Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn’s and Colitis (AOCC) meeting in Seoul. Intest Res. 2016; 14:231–239.
Article
24. Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn’s disease. Part 2: Management. J Gastroenterol Hepatol. 2016; 31:56–68.
Article
25. Neary B, Doherty G, Rafter N, Gibson D. A structured care pathway improves quality of care for acute severe ulcerative colitis. J Crohns Colitis. 2017; 11(Suppl 1):S257–S258.
Article
26. Walsh AJ, Weltman M, Burger D, et al. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2013; 7:e449–e456.
Article
27. Allen PB, Olivera P, Emery P, et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017; 45:1058–1072.
Article
28. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549.
Article
29. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133:412–422.
Article
30. Atreya R, Neurath MF. Current and future targets for mucosal healing in inflammatory bowel disease. Visc Med. 2017; 33:82–88.
Article
31. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338.
32. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018; 390:2779–2789.
Article
33. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015; 386:1825–1834.
Article
34. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014; 12:978–985.
Article
35. Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014; 63:1092–1102.
Article
36. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103:3167–3182.
Article
37. M’Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013; 6:33–47.
Article
38. Berry SK, Melmed GY. Quality indicators in inflammatory bowel disease. Intest Res. 2018; 16:43–47.
Article
39. Kim ES, Kim SK, Jang BI, et al. Disease activity patterns recorded using a mobile monitoring system are associated with clinical outcomes of patients with Crohn’s disease. Dig Dis Sci. 2018; 63:2220–2230.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr